BEIJING (Reuters) – Chinese company Sinovac Biotech plans to begin analyzing knowledge of the latest human trials on its candidate coronavirus vaccine this year to determine whether it is effective enough to seek regulatory approval before the trial ends, its president said Thursday.
The plan puts the Chinese vaccine developer on par with some of its Western rivals who must compare the effectiveness of their vaccines just a few months before phase 3 clinical trials.
The U. S. drug manufacturer Pfizer is expected to publish in October whether its experimental vaccine is working, while Moderna said interim research into its vaccine testing knowledge is expected to take a position in November.
Sinovac may begin evaluating CoronaVac’s ability to others as soon as researchers practice that at least 61 control subjects are in poor health with the disease, EXECUTIVE Director Yin Weidong said at a press conference.
Yin said the company hopes to deliver its experimental coronavirus vaccine to more South American countries by outsourcing safe production procedures to a spouse in Brazil.
Global vaccine manufacturers such as Sinovac and AstraZeneca have partnered in Brazil to conduct complex trials of their candidate vaccines in South America’s largest country, which has the third largest number of infections in the world.
Sinovac plans to supply semi-finished products to its spouse Butantan Institute, which will carry out filling and packaging and supply finished products to other South American countries.
China has included Sinovac’s CoronaVac in its emergency use program introduced in July, but complex tests have not yet been completed, raising considerations among protection experts.
It is also very likely that the Brazilian state of Sao Paulo will begin vaccinating its population with the Sinovac vaccine in mid-December, pending regulatory approval, its governor said.
Yin stated that the corporate is willing to collaborate and percentage of knowledge with other countries about the emergency use of vaccines if they wish, and is in talks with Chile, among other countries, to conduct Phase 3 clinical studies.
“Different countries have their own characteristics about emergency use authorization,” Yin said, adding that he knew if they would stay in China.
Another candidate vaccine evolved through a subsidiary of China’s state-supported national pharmaceutical organization (Sinopharm), which was approved for emergency use last week in the United Arab Emirates, where it is still being tested.
(Interactive chart that tracks global coronavirus: https://graphics. reuters. com/world-coronavirus-tracker-and-maps)
(Reporting through Thomas Peter and Roxanne Liu in Beijing; Editing via Clarence Fernandez, Miyoung Kim and Nick Macfie)
Subscribe
Sign up for our news blast.